Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.

James, Rani; Thriveni, K; Krishnamoorthy, Lakshmi; Deshmane, Vijayalaxmi; Bapsy, P P; Ramaswamy, Girija.
Artículo en Inglés | IMSEAR | ID: sea-135352

Documentos relacionados

  1. Association between Homologous Recombination Repair Defect Status and Long-Term Prognosis of Early HER2-Low Breast Cancer: A Retrospective Cohort Study.
  2. Validation of the RSClin risk calculator in the National Cancer Data Base.
  3. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.
  4. Her-2/neu gene amplification and its correlation with other prognostic factors in Iranian breast cancer patients.
  5. Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients.
  6. Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy.
  7. ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
  8. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
  9. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
  10. PhiHER2: phenotype-informed weakly supervised model for HER2 status prediction from pathological images.